Mylan Inc. has released fenofibric acid delayed-release capsules, a medication for treating high levels of cholesterol and triglycerides.


Mylan, Trilipix, generic version, Mylan Pharmaceuticals, Abbott, fenofibric acid delayed-release capsules, cholesterol, triglycerides


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Mylan launches Trilipix generic

July 15th, 2013

PITTSBURGH – Mylan Inc. has released fenofibric acid delayed-release capsules, a medication for treating high levels of cholesterol and triglycerides.

The company said Monday that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched the product in dosages of 45 mg and 135 mg.

Fenofibric acid delayed-release capsules are the generic version of Abbott's Trilipix Capsules, according to Mylan.

Mylan said it received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for the product.

The medication is indicated as an adjunct to diet in combination with a statin to reduce triglycerides and increase high-density lipoprotein cholesterol in patients with mixed dyslipidemia.

Mylan reported that fenofibric acid delayed-release capsules (45 mg and 135 mg) had U.S. sales of about $553.6 million for the 12 months ended March 31, based on IMS Health figures.

More Supplier News Breaks >>
Advertisement